Will Biogen achieve all milestone payments for the HI-Bio acquisition by end of 2026? | Binary | | | 7 months ago | |
Will Felzartamab be approved by the FDA by end of 2025? | Binary | | | 7 months ago | |
What will be Felzartamab's market share within its first year of launch? | Categorical | | | 7 months ago | |
Will Biogen's stock price increase within 6 months following the HI-Bio acquisition announcement? | Binary | | | 7 months ago | |
How will Biogen's stock price react the day after the HI-Bio acquisition announcement? | Categorical | | | 7 months ago | |
How will HI-Bio's integration impact Biogen's revenue by the end of 2025? | Categorical | | | 7 months ago | |
What will be the number of employees at 23andMe by the end of 2025? | Categorical | | | 1 month ago | |
Will 23andMe achieve its cost-saving target of $35 million by June 30, 2025? | Binary | | | 1 month ago | |
Will 23andMe return to revenue growth by the end of 2025? | Binary | | | 1 month ago | |
Will Anne Wojcicki remain CEO of 23andMe by the end of 2025? | Binary | | | 1 month ago | |
What will be the main focus area for 23andMe's business strategy by the end of 2025? | Categorical | | | 1 month ago | |
How will 23andMe's stock perform relative to NASDAQ by June 30, 2025? | Categorical | | | 1 month ago | |
